Compare HRTX & FMY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | HRTX | FMY |
|---|---|---|
| Founded | 1983 | 2005 |
| Country | United States | United States |
| Employees | 128 | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Finance/Investors Services |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 61.2M | 49.0M |
| IPO Year | 2007 | 2005 |
| Metric | HRTX | FMY |
|---|---|---|
| Price | $0.31 | $11.35 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 2 | 0 |
| Target Price | ★ $4.50 | N/A |
| AVG Volume (30 Days) | ★ 2.0M | 3.3K |
| Earning Date | 05-11-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 6.98% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $154,904,000.00 | N/A |
| Revenue This Year | $15.28 | N/A |
| Revenue Next Year | $20.29 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 7.36 | N/A |
| 52 Week Low | $0.30 | $11.35 |
| 52 Week High | $1.58 | $12.36 |
| Indicator | HRTX | FMY |
|---|---|---|
| Relative Strength Index (RSI) | 40.13 | 42.03 |
| Support Level | $0.30 | N/A |
| Resistance Level | $0.34 | $11.89 |
| Average True Range (ATR) | 0.02 | 0.15 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 41.64 | 7.55 |
Heron Therapeutics Inc is a commercial-stage biotechnology company. The company is focused on improving the lives of patients by developing treatments and commercializing therapeutic solutions to address some of the unmet patient needs. The company's product portfolio consists of APONVIE, SUSTOL, ZYNRELEF, and CINVANTI.
First Trust Mortgage Income Fund is a United States-based diversified, closed-end management investment company. The fund's primary investment objective is to seek a high level of current income. Its secondary investment objective is to preserve capital. The fund pursues its objectives by investing predominantly in mortgage-backed securities representing part ownership in a pool of either residential or commercial mortgage loans that, in the opinion of the Fund's investment advisor, offer an attractive combination of credit quality, yield, and maturity.